January 2021:The first dual-target CAR-T IND was approved;
January 2021:Hrain was recognized as "National High-tech Enterprise";
March 2020: Hrain’s CAR-T cell preparation center officially started construction;
September 2020: Completed B+ round financing;
October 2020:the first dual-target CAR-T IND application in China was accepted by CDE;
October 2020: the intellectual property management system was certified by the national authoritative standard system (IPMS);
December 2020: Hrain CAR-T cell preparation center was completed;
May 2019: Hrain recognized as Pudong Enterprise-run Postdoctoral Research Works;
September 2019: Completed B round financing;
January 2018: The first success of CAR-T infusion by Hrain in a patient with liver cancer;
March 2018: Completed A round financing;
April 2018: Started the construction of the Cell Processing Center;
July 2018: Completed A+ round financing;
July 2018: Two anti-human CD19 T cell injections were approved by NMPA for clinical trials;
July 2018: Won the 2018 Frost & Sullivan's China New Economy Award — Excellence in Innovation;
September 2018: Officially launched Shanghai Zhangjiang Jinshan Biological Base;
October 2018: Held Hrain Phase I Clinical Trial Kick-off Meeting for anti-human CD19 T cell injection(against r/r Lymphoma);
November 2018: Hrain products were included into the biomedical exhibition area of Zhangjiang Science City (inspected by General Secretary Xi Jinping);
November 2018: Successfully held the 13th Annual Meeting of Chinese Society for Immunology - Hrain Satellite Conference;
December 2018: Anti-human BCMA T cell injection was approved for clinical use.
January 2017: The first success of CAR-T infusion by Hrain in a patient with multiple myeloma;
February 2017: Launched the expansion of the platform to 3,000 square meters;
December 2017: Started the cooperation with Shanghai Changzheng Hospital and had the 11st clinical cooperation centers.
February 2016: Registered another 2 clinical trials on ClinicalTrials.gov, reaching 8 in total;
February 2016: The first success of CAR-T infusion by Hrain in a patient with leukemia.
April 2015: Completed the construction of the technology platform in Zhangjiang;
July 2015: Hrain Biotechnology founded;
September 2015: Held the CAR-T Clinical Trial Kick-off Meeting;
September 2015: Started the cooperation with Chongqing Xinqiao Hospital -- the first CAR-T clinical cooperation center;
October 2015: Realized stable production of virus-based CAR-Ts;
December 2015: The first success of CAR-T infusion by Hrain in a patient with B-cell lymphoma.